CARLSBAD, Calif. and SINGAPORE, June 14, 2012 /PRNewswire/ -- Life Technologies Corporation — (NASDAQ: LIFE) today announced that it has established a Global Instrument Center of Excellence in Singapore, to address strong customer demand around the world.
The center will design and manufacture Life Technologies products, including next-generation sequencing and molecular diagnostic instruments for thousands of customers within the region and outside Asia Pacific. It is Life Technologies only internal instrument manufacturing facility outside of the United States.
Life Technologies provides customers with systems, consumables and services that enable researchers to accelerate scientific and medical advancements. Asia Pacific is one of the company's key growth drivers; Asia Pacific sales (excluding Japan) grew over 9 percent in 2011. Life Technology's volume of items shipped per day in the region has increased fourfold, with dramatically improved order fulfillment time that is up to 50 percent faster in most cases.
"The life science instrumentation industry in Singapore has been expanding rapidly due to the strong market growth in Asia," said Kevin Lai, Director of the Biomedical Sciences Group for the Singapore Economic Development Board. "This new Global Instrument Center of Excellence is an example of how leading life science instrumentation companies are increasingly looking to Singapore as an integrated location for complex analytical instrument manufacturing, research and development of next generation platforms, and Regional Headquarters for Asia."
"The scientific community in Asia Pacific is growing at a rapid rate," said Mark Smedley, President of Asia Pacific and Japan for Life Technologies. "By establishing the Instrument Center of Excellence in Singapore we are providing our global customers innovative technologies more efficiently, while helping them advance their research even faster."
The center is a testament to Life Technologies' long standing commitment and investment in the scientific research and development taking place in Asia Pacific. Last year the company opened a regional distribution center in Singapore's Tuas Biomedical Park to enhance the quality, availability and timely delivery of its product lines to its thriving customer base in Asia.
About Life Technologies
Life Technologies Corporation is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables, represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment
to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or
conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact
SOURCE Life Technologies Corporation